Showing 1061-1070 of 1225 results for "".
- Non-Contact Panretinal Photocoagulation for Navilas 577s Introduced at AAO 2018https://modernod.com/news/non-contact-panretinal-photocoagulation-for-navilas-577s-introduced-at-aao-2018/2479753/At the AAO 2018 meeting in Chicago, OD-OS is launching a new widefield objective which brings non-contact panretinal photocoagulation with access to the far periphery (ora serrata) to the Navilas 577s Laser System. The new option for peripheral treatments can further enhance compliance of sensiti
- Silicon Valley Eye Doctor Named Optometrist of the Year By American Optometric Associationhttps://modernod.com/news/silicon-valley-eye-doctor-named-optometrist-of-the-year-by-american-optometric-association/2480071/The California Optometric Association (COA) announced that David M. Redman, OD, has been named the “Optometrist of the Year” for 2017 by the American Optometric Association (AOA). Dr. Redman is a practicing optometrist and partner in Precision Eyecare Centers in San Jose and Mountain View. Dr. Re
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025https://modernod.com/news/johnson-johnson-marks-100000-us-implants-of-tecnis-odyssey-iol-and-showcases-innovations-at-aao-2025/2484177/Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch. The company will highlight this milestone alongside new data presentations and technology showcases
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Johnson & Johnson Launches Tecnis Odyssey IOL in Europe, the Middle East, and Canadahttps://modernod.com/news/johnson-johnson-launches-tecnis-odyssey-iol-in-europe-the-middle-east-and-canada/2482853/Johnson & Johnson announced that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of Tecnis Odyssey IOL in Europe, the Middle East, and Canada. According to J&J, the new full visual range IOL offers high-quality and c
- Johnson & Johnson to Present New Data for Tecnis Odyssey at ASCRShttps://modernod.com/news/johnson-johnson-to-present-new-data-for-tecnis-odyssey-at-ascrs/2482753/Johnson & Johnson will present data supporting the performance of the next-generation Tecnis Odyssey IOL at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Los Angeles. J&J is featuring 22 company sponsored and investigator led studies
- Topcon Healthcare Appoints Christian Odaker as Chief Technology Officerhttps://modernod.com/news/topcon-healthcare-appoints-christian-odaker-as-chief-technology-officer/2482599/Topcon Healthcare announced the appointment of Christian Odaker, PhD, to the role of Chief Technology Officer (CTO). Dr. Odaker willsupport the company's 'Healthcare from the Eye' initiative, which leverages AI-powered disease detection and management using da
- Johnson & Johnson to Showcase Tecnis Odyssey IOL and Present New Research at AAO 2024https://modernod.com/news/johnson-johnson-to-showcase-tecnis-odyssey-iol-and-present-new-research-at-aao-2024/2482501/Johnson & Johnson will highlight its latest innovations in eye health during the 2024 American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21 in Chicago. Among the company's spotlight advancements is the Tecnis Odyssey IOL, a new presbyopia-correcting IOL t
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show